T1	tradename 93 98	DOXIL
T3	tradename 160 165	DOXIL
T5	tradename 167 172	DOXIL
T7	activeingredient 174 199	doxorubicin hydrochloride
T9	nanoparticle 200 208	liposome
T11	routeofadministration 225 236	intravenous
T13	activeingredient 481 496	doxorubicin HCl
T15	dose 508 518	550 mg/m2.
T17	chemoclass 1137 1177	anthracycline topoisomerase II inhibitor
T19	indication 1193 1207	Ovarian cancer
T21	indication 1260 1289	AIDS-related Kaposi's Sarcoma
T23	indication 1373 1389	Multiple Myeloma
T25	co-administereddrug 1416 1426	bortezomib
T27	co-administereddrug 1472 1482	bortezomib
T29	tradename 1566 1571	DOXIL
T31	indication 1817 1832	Ovarian cancer:
T33	dose 1833 1841	50 mg/m2
T35	routeofadministration 1842 1844	IV
T37	frequency 1845 1858	every 4 weeks
T39	indication 1865 1895	AIDS-related Kaposi's Sarcoma:
T41	dose 1896 1904	20 mg/m2
T43	routeofadministration 1905 1907	IV
T45	frequency 1908 1921	every 3 weeks
T47	indication 1928 1945	Multiple Myeloma:
T49	dose 1946 1954	30 mg/m2
T51	routeofadministration 1955 1957	IV
T53	co-administereddrug 1977 1987	bortezomib
T55	activeingredient 2033 2047	 hydrochloride
T57	nanoparticle 2054 2063	liposomal
T59	activeingredient 2188 2203	doxorubicin HCl
T61	tradename 2225 2230	DOXIL
T63	adversereaction 2281 2299	Hand-Foot Syndrome
T65	adversereaction 2373 2395	Embryo fetal Toxicity:
T67	adversereaction 2578 2586	asthenia
T69	adversereaction 2588 2595	fatigue
T71	adversereaction 2597 2602	fever
T73	adversereaction 2604 2612	anorexia
T75	adversereaction 2614 2620	nausea
T77	adversereaction 2622 2630	vomiting
T79	adversereaction 2632 2642	stomatitis
T81	adversereaction 2644 2652	diarrhea
T83	adversereaction 2654 2666	constipation
T85	adversereaction 2668 2686	hand-foot syndrome
T87	adversereaction 2688 2692	rash
T89	adversereaction 2694 2705	neutropenia
T91	adversereaction 2707 2723	thrombocytopenia
T93	adversereaction 2729 2735	anemia
T95	company 2788 2804	Janssen Products
T97	company 2806 2808	LP
T99	indication 3138 3152	Ovarian Cancer
T101	indication 3157 3186	AIDS-Related Kaposi's Sarcoma
T103	indication 3191 3207	Multiple Myeloma
T105	indication 3272 3286	Ovarian Cancer
T107	indication 3291 3320	AIDS-Related Kaposi's Sarcoma
T109	indication 3325 3341	Multiple Myeloma
T111	adversereaction 3555 3569	Cardiomyopathy
T113	adversereaction 3574 3600	Infusion-Related Reactions
T115	adversereaction 3605 3629	Hand-Foot Syndrome (HFS)
T117	adversereaction 3634 3658	Secondary Oral Neoplasms
T119	adversereaction 3663 3684	Embryo fetal Toxicity
T121	indication 4171 4185	Ovarian Cancer
T123	indication 4191 4220	AIDS-Related Kaposi's Sarcoma
T125	indication 4226 4242	Multiple Myeloma
T127	tradename 4508 4513	DOXIL
T129	activeingredient 4515 4530	doxorubicin HCl
T131	nanoparticle 4531 4539	liposome
T133	adversereaction 4561 4578	myocardial damage
T135	adversereaction 4590 4614	congestive heart failure
T137	activeingredient 4648 4663	doxorubicin HCl
T139	dose 4675 4685	550 mg/m2.
T141	tradename 4765 4770	DOXIL
T143	adversereaction 4784 4798	cardiotoxicity
T145	dose 4858 4871	450-550 mg/m2
T147	adversereaction 5215 5223	flushing
T149	adversereaction 5225 5244	shortness of breath
T151	adversereaction 5246 5261	facial swelling
T153	adversereaction 5263 5271	headache
T155	adversereaction 5273 5279	chills
T157	adversereaction 5281 5290	back pain
T159	adversereaction 5292 5324	tightness in the chest or throat
T161	adversereaction 5333 5344	hypotension
T163	tradename 5404 5410	DOXIL.
T165	indication 5583 5597	Ovarian Cancer
T167	tradename 5599 5604	DOXIL
T169	indication 5653 5667	ovarian cancer
T171	indication 5748 5777	AIDS-Related Kaposi's Sarcoma
T173	tradename 5778 5783	DOXIL
T175	indication 5818 5847	AIDS-related Kaposi's sarcoma
T177	indication 5941 5957	Multiple Myeloma
T179	tradename 5958 5963	DOXIL
T181	co-administereddrug 5985 5995	bortezomib
T183	indication 6045 6061	multiple myeloma
T185	co-administereddrug 6095 6105	bortezomib
T187	tradename 6218 6223	DOXIL
T189	activeingredient 6228 6243	doxorubicin HCl
T191	routeofadministration 6310 6321	intravenous
T193	indication 6372 6386	Ovarian Cancer
T195	tradename 6411 6416	DOXIL
T197	dose 6420 6428	50 mg/m2
T199	routeofadministration 6429 6442	intravenously
T201	frequency 6459 6472	every 28 days
T203	indication 6531 6552	AIDS-Related Kaposi's
T205	indication 6554 6557	The
T207	tradename 6578 6583	DOXIL
T209	dose 6587 6595	20 mg/m2
T211	routeofadministration 6596 6609	intravenously
T213	frequency 6626 6639	every 21 days
T215	indication 6698 6714	Multiple Myeloma
T217	tradename 6739 6744	DOXIL
T219	dose 6748 6756	30 mg/m2
T221	routeofadministration 6757 6770	intravenously
T223	frequency 6787 6816	on day 4 of each 21-day cycle
T225	duration 6821 6833	eight cycles
T227	tradename 6900 6905	DOXIL
T229	co-administereddrug 6912 6922	bortezomib
T231	tradename 7031 7036	DOXIL
T233	adversereaction 7120 7138	Hand-Foot Syndrome
T235	adversereaction 7140 7150	Stomatitis
T237	adversereaction 7203 7227	Hand-Foot Syndrome (HFS)
T239	tradename 7694 7699	DOXIL
T241	tradename 8089 8094	DOXIL
T243	tradename 8378 8383	DOXIL
T245	adversereaction 8418 8428	Stomatitis
T247	tradename 8754 8759	DOXIL
T249	tradename 9212 9218	DOXIL.
T251	tradename 9440 9446	DOXIL.
T253	adversereaction 9463 9479	Thrombocytopenia
T255	tradename 9887 9892	DOXIL
T257	co-administereddrug 9944 9954	Bortezomib
T259	tradename 9965 9970	DOXIL
T261	adversereaction 10515 10531	neuropathic pain
T263	adversereaction 10535 10556	peripheral neuropathy
T265	tradename 10597 10603	DOXIL.
T267	co-administereddrug 10613 10623	bortezomib
T269	tradename 10704 10709	DOXIL
T271	inactiveingredient 10744 10752	Dextrose
T273	inactiveingredient 10838 10846	Dextrose
T275	tradename 10907 10912	DOXIL
T277	tradename 11251 11256	DOXIL
T279	tradename 11516 11521	DOXIL
T281	tradename 11577 11582	DOXIL
T283	tradename 12084 12089	DOXIL
T285	tradename 12177 12182	DOXIL
T287	tradename 12303 12309	DOXIL:
T289	activeingredient 12310 12325	doxorubicin HCl
T291	nanoparticle 12326 12335	liposomal
T293	dose 12372 12382	20mg/10 mL
T295	dose 12387 12396	50mg/25mL
T297	activeingredient 12397 12412	doxorubicin HCl
T299	nanoparticle 12435 12444	liposomal
T301	tradename 12479 12484	DOXIL
T303	activeingredient 12600 12615	doxorubicin HCl
T305	adversereaction 12677 12691	Cardiomyopathy
T307	activeingredient 12693 12708	Doxorubicin HCl
T309	adversereaction 12723 12740	myocardial damage
T311	adversereaction 12752 12783	acute left ventricular failure.
T313	adversereaction 12796 12810	cardiomyopathy
T315	activeingredient 12816 12831	doxorubicin HCl
T317	tradename 12922 12927	DOXIL
T319	adversereaction 12949 12965	cardiac toxicity
T321	tradename 13071 13076	DOXIL
T323	adversereaction 13090 13104	cardiotoxicity
T325	dose 13164 13177	450-550 mg/m2
T327	adversereaction 13180 13194	Cardiotoxicity
T329	adversereaction 13500 13524	congestive heart failure
T331	adversereaction 13556 13571	cardiotoxicity.
T333	tradename 13667 13672	DOXIL
T335	tradename 13781 13786	DOXIL
T337	tradename 14065 14071	DOXIL:
T339	adversereaction 14072 14080	flushing
T341	adversereaction 14082 14101	shortness of breath
T343	adversereaction 14103 14118	facial swelling
T345	adversereaction 14120 14128	headache
T347	adversereaction 14130 14136	chills
T349	adversereaction 14138 14148	chest pain
T351	adversereaction 14150 14159	back pain
T353	adversereaction 14161 14194	tightness in the chest and throat
T355	adversereaction 14196 14201	fever
T357	adversereaction 14203 14214	tachycardia
T359	adversereaction 14216 14224	pruritus
T361	adversereaction 14226 14230	rash
T363	adversereaction 14232 14240	cyanosis
T365	adversereaction 14242 14249	syncope
T367	adversereaction 14251 14263	bronchospasm
T369	adversereaction 14265 14271	asthma
T371	adversereaction 14273 14278	apnea
T373	adversereaction 14284 14296	hypotension.
T375	indication 14394 14408	ovarian cancer
T377	tradename 14422 14427	DOXIL
T379	tradename 14622 14627	DOXIL
T381	tradename 14930 14936	DOXIL.
T383	tradename 14946 14951	DOXIL
T385	tradename 15195 15200	DOXIL
T387	adversereaction 15276 15300	Hand-Foot Syndrome (HFS)
T389	tradename 15361 15366	DOXIL
T391	tradename 15457 15470	DOXIL-treated
T393	tradename 15593 15598	DOXIL
T395	tradename 15710 15715	DOXIL
T397	tradename 15815 15820	DOXIL
T399	adversereaction 15860 15884	Secondary Oral Neoplasms
T401	adversereaction 15885 15907	Secondary oral cancers
T403	adversereaction 15919 15942	squamous cell carcinoma
T405	tradename 16054 16060	DOXIL.
T407	tradename 16122 16127	DOXIL
T409	adversereaction 16295 16317	secondary oral cancer.
T411	nanoparticle 16388 16397	liposomal
T413	activeingredient 16398 16409	doxorubicin
T415	adversereaction 16439 16452	skin toxicity
T417	adversereaction 16457 16466	mucositis
T419	adversereaction 16534 16561	oral secondary malignancies
T421	adversereaction 16605 16625	Embryofetal Toxicity
T423	tradename 16648 16653	DOXIL
T425	tradename 16779 16784	DOXIL
T427	tradename 17014 17019	DOXIL
T429	adversereaction 17179 17193	Cardiomyopathy
T431	adversereaction 17232 17258	Infusion-Related Reactions
T433	adversereaction 17297 17315	Hand-Foot Syndrome
T435	adversereaction 17354 17378	Secondary Oral Neoplasms
T437	tradename 17474 17479	DOXIL
T439	adversereaction 17484 17492	asthenia
T441	adversereaction 17494 17501	fatigue
T443	adversereaction 17503 17508	fever
T445	adversereaction 17510 17516	nausea
T447	adversereaction 17518 17528	stomatitis
T449	adversereaction 17530 17538	vomiting
T451	adversereaction 17540 17548	diarrhea
T453	adversereaction 17550 17562	constipation
T455	adversereaction 17564 17572	anorexia
T457	adversereaction 17574 17592	hand-foot syndrome
T459	adversereaction 17594 17598	rash
T461	adversereaction 17603 17614	neutropenia
T463	adversereaction 17616 17632	thrombocytopenia
T465	adversereaction 17637 17643	anemia
T467	tradename 17947 17952	DOXIL
T469	indication 17999 18013	ovarian cancer
T471	indication 18033 18062	AIDS-related Kaposi's sarcoma
T473	indication 18086 18103	multiple myeloma.
T475	tradename 18189 18194	DOXIL
T477	indication 18198 18212	ovarian cancer
T479	indication 18217 18247	AIDS-Related Kaposi's sarcoma.
T481	indication 18264 18278	Ovarian Cancer
T483	indication 18362 18376	ovarian cancer
T485	tradename 18390 18395	DOXIL
T487	tradename 18535 18540	DOXIL
T489	tradename 18839 18844	DOXIL
T491	adversereaction 18890 18901	Neutropenia
T493	adversereaction 18950 18956	Anemia
T495	adversereaction 19007 19023	Thrombocytopenia
T497	tradename 19219 19224	DOXIL
T499	adversereaction 19370 19378	Asthenia
T501	adversereaction 19389 19394	Fever
T503	adversereaction 19407 19431	Mucous Membrane Disorder
T505	adversereaction 19445 19454	Back Pain
T507	adversereaction 19469 19478	Infection
T509	adversereaction 19492 19500	Headache
T511	adversereaction 19526 19532	Nausea
T513	adversereaction 19543 19553	Stomatitis
T515	adversereaction 19566 19574	Vomiting
T517	adversereaction 19586 19594	Diarrhea
T519	adversereaction 19609 19617	Anorexia
T521	adversereaction 19632 19641	Dyspepsia
T523	adversereaction 19666 19675	Dizziness
T525	adversereaction 19700 19711	Pharyngitis
T527	adversereaction 19724 19731	Dyspnea
T529	adversereaction 19746 19761	Cough increased
T531	adversereaction 19795 19813	Hand-foot syndrome
T533	adversereaction 19826 19830	Rash
T535	adversereaction 19845 19853	Alopecia
T537	indication 19942 19956	ovarian cancer
T539	frequency 19981 19997	every four weeks
T541	adversereaction 20046 20058	vasodilation
T543	adversereaction 20060 20071	tachycardia
T545	adversereaction 20073 20093	deep vein thrombosis
T547	adversereaction 20095 20106	hypotension
T549	adversereaction 20108 20123	cardiac arrest.
T551	adversereaction 20136 20151	oral moniliasis
T553	adversereaction 20153 20169	mouth ulceration
T555	adversereaction 20171 20182	esophagitis
T557	adversereaction 20184 20193	dysphagia
T559	adversereaction 20195 20210	rectal bleeding
T561	adversereaction 20212 20218	ileus.
T563	adversereaction 20247 20258	ecchymosis.
T565	adversereaction 20287 20298	dehydration
T567	adversereaction 20300 20311	weight loss
T569	adversereaction 20313 20331	hyperbilirubinemia
T571	adversereaction 20333 20344	hypokalemia
T573	adversereaction 20346 20359	hypercalcemia
T575	adversereaction 20361 20374	hyponatremia.
T577	adversereaction 20385 20395	somnolence
T579	adversereaction 20397 20406	dizziness
T581	adversereaction 20408 20419	depression.
T583	adversereaction 20434 20442	rhinitis
T585	adversereaction 20444 20453	pneumonia
T587	adversereaction 20455 20464	sinusitis
T589	adversereaction 20466 20476	epistaxis.
T591	adversereaction 20499 20507	pruritus
T593	adversereaction 20509 20527	skin discoloration
T595	adversereaction 20529 20549	vesiculobullous rash
T597	adversereaction 20551 20569	maculopapular rash
T599	adversereaction 20571 20593	exfoliative dermatitis
T601	adversereaction 20595 20608	herpes zoster
T603	adversereaction 20610 20618	dry skin
T605	adversereaction 20620 20634	herpes simplex
T607	adversereaction 20636 20653	fungal dermatitis
T609	adversereaction 20655 20667	furunculosis
T611	adversereaction 20669 20674	acne.
T613	adversereaction 20692 20706	conjunctivitis
T615	adversereaction 20708 20724	taste perversion
T617	adversereaction 20726 20735	dry eyes.
T619	adversereaction 20746 20769	urinary tract infection
T621	adversereaction 20771 20780	hematuria
T623	adversereaction 20782 20801	vaginal moniliasis.
T625	indication 20818 20847	AIDS-Related Kaposi's Sarcoma
T627	indication 20931 20960	AIDS-related Kaposi's sarcoma
T629	tradename 21018 21023	DOXIL
T631	dose 21059 21073	10 to 40 mg/m2
T633	frequency 21074 21093	every 2 to 3 weeks.
T635	dose 21287 21295	20 mg/m2
T637	tradename 21299 21304	DOXIL
T639	frequency 21305 21323	every 2 to 3 weeks
T641	duration 21350 21360	4.2 months
T643	duration 21368 21389	1 day to 26.6 months)
T645	dose 21422 21431	120 mg/m2
T647	dose 21439 21458	3.3 to 798.6 mg/m2)
T649	dose 21505 21514	450 mg/m2
T651	indication 22433 22462	AIDS-related Kaposi's sarcoma
T653	adversereaction 22476 22492	myelosuppression
T655	adversereaction 22494 22519	cardiac adverse reactions
T657	adversereaction 22521 22547	infusion-related reactions
T659	adversereaction 22549 22562	toxoplasmosis
T661	adversereaction 22564 22567	HFS
T663	adversereaction 22569 22578	pneumonia
T665	adversereaction 22580 22593	cough/dyspnea
T667	adversereaction 22595 22602	fatigue
T669	adversereaction 22604 22618	optic neuritis
T671	adversereaction 22620 22649	progression of a non-KS tumor
T673	adversereaction 22651 22672	allergy to penicillin
T675	tradename 22776 22781	DOXIL
T677	indication 22786 22815	AIDS-related Kaposi's sarcoma
T679	indication 22922 22951	AIDS-Related Kaposi's Sarcoma
T681	indication 23024 23062	AIDS-Related Kaposi's Kaposi's Sarcoma
T683	adversereaction 23090 23101	Neutropenia
T685	adversereaction 23146 23152	Anemia
T687	adversereaction 23195 23211	Thrombocytopenia
T689	indication 23748 23785	AIDS-Related Kaposi's Sarcoma Adverse
T691	indication 23855 23897	AIDS-Related AIDS-Related Kaposi's Sarcoma
T693	adversereaction 23934 23940	Nausea
T695	adversereaction 23949 23957	Asthenia
T697	adversereaction 23965 23970	Fever
T699	adversereaction 23977 23985	Alopecia
T701	adversereaction 23992 24021	Alkaline Phosphatase Increase
T703	adversereaction 24030 24038	Vomiting
T705	adversereaction 24045 24053	Diarrhea
T707	adversereaction 24060 24070	Stomatitis
T709	adversereaction 24077 24092	Oral Moniliasis
T711	indication 24599 24629	AIDS-related Kaposi's sarcoma.
T713	adversereaction 24668 24676	headache
T715	adversereaction 24678 24687	back pain
T717	adversereaction 24689 24698	infection
T719	adversereaction 24700 24717	allergic reaction
T721	adversereaction 24719 24726	chills.
T723	adversereaction 24745 24755	chest pain
T725	adversereaction 24757 24768	hypotension
T727	adversereaction 24770 24782	tachycardia.
T729	adversereaction 24796 24810	herpes simplex
T731	adversereaction 24812 24816	rash
T733	adversereaction 24818 24826	itching.
T735	adversereaction 24840 24856	mouth ulceration
T737	adversereaction 24858 24866	anorexia
T739	adversereaction 24868 24878	dysphagia.
T741	adversereaction 24908 24921	SGPT increase
T743	adversereaction 24923 24934	weight loss
T745	adversereaction 24936 24955	hyperbilirubinemia.
T747	adversereaction 24965 24972	dyspnea
T749	adversereaction 24974 24983	pneumonia
T751	adversereaction 24985 24994	dizziness
T753	adversereaction 24996 25007	somnolence.
T755	adversereaction 25050 25056	sepsis
T757	adversereaction 25058 25068	moniliasis
T759	adversereaction 25070 25085	cryptococcosis.
T761	adversereaction 25104 25120	thrombophlebitis
T763	adversereaction 25122 25136	cardiomyopathy
T765	adversereaction 25138 25149	palpitation
T767	adversereaction 25151 25170	bundle branch block
T769	adversereaction 25172 25196	congestive heart failure
T771	adversereaction 25198 25210	heart arrest
T773	adversereaction 25212 25222	thrombosis
T775	adversereaction 25224 25247	ventricular arrhythmia.
T777	adversereaction 25261 25271	hepatitis.
T779	adversereaction 25311 25322	dehydration
T781	adversereaction 25338 25352	cough increase
T783	adversereaction 25354 25366	pharyngitis.
T785	adversereaction 25390 25408	maculopapular rash
T787	adversereaction 25410 25424	herpes zoster.
T789	adversereaction 25443 25459	taste perversion
T791	adversereaction 25461 25476	conjunctivitis.
T793	tradename 25564 25569	DOXIL
T795	dose 25571 25580	30 mg/m2)
T797	co-administereddrug 25613 25623	bortezomib
T799	dose 25625 25634	1.3 mg/m2
T801	routeofadministration 25635 25639	i.v.
T803	frequency 25671 25684	every 3 weeks
T805	tradename 25775 25780	DOXIL
T807	co-administereddrug 25783 25793	bortezomib
T809	duration 25848 25858	4.5 months
T811	duration 25866 25889	21 days to 13.5 months)
T813	tradename 26089 26094	DOXIL
T815	co-administereddrug 26115 26125	bortezomib
T817	indication 26130 26147	multiple myeloma.
T819	indication 26247 26263	Multiple Myeloma
T821	tradename 26269 26274	DOXIL
T823	co-administereddrug 26295 26305	Bortezomib
T825	tradename 26323 26328	DOXIL
T827	co-administereddrug 26331 26352	bortezomib Bortezomib
T829	adversereaction 26446 26457	Neutropenia
T831	adversereaction 26470 26486	Thrombocytopenia
T833	adversereaction 26499 26505	Anemia
T835	adversereaction 26571 26578	Fatigue
T837	adversereaction 26589 26596	Pyrexia
T839	adversereaction 26607 26615	Asthenia
T841	adversereaction 26655 26661	Nausea
T843	adversereaction 26672 26680	Diarrhea
T845	adversereaction 26691 26699	Vomiting
T847	adversereaction 26710 26722	Constipation
T849	adversereaction 26733 26753	Mucositis/Stomatitis
T851	adversereaction 26767 26781	Abdominal pain
T853	adversereaction 26821 26834	Herpes zoster
T855	adversereaction 26844 26858	Herpes simplex
T857	adversereaction 26883 26899	Weight decreased
T859	adversereaction 26948 26956	Anorexia
T861	adversereaction 26996 27018	Peripheral Neuropathy1
T863	adversereaction 27030 27039	Neuralgia
T865	adversereaction 27050 27073	Paresthesia/dysesthesia
T867	adversereaction 27138 27143	Cough
T869	adversereaction 27195 27200	Rash2
T871	adversereaction 27211 27229	Hand-foot syndrome
T873	adversereaction 27310 27339	peripheral sensory neuropathy
T875	adversereaction 27341 27362	neuropathy peripheral
T877	adversereaction 27364 27378	polyneuropathy
T879	adversereaction 27380 27407	peripheral motor neuropathy
T881	adversereaction 27413 27423	neuropathy
T883	adversereaction 27478 27482	rash
T885	adversereaction 27484 27501	rash erythematous
T887	adversereaction 27503 27515	rash macular
T889	adversereaction 27517 27536	rash maculo-papular
T891	adversereaction 27538 27551	rash pruritic
T893	adversereaction 27553 27569	exfoliative rash
T895	adversereaction 27575 27591	rash generalized
T897	tradename 27704 27710	DOXIL.
T899	adversereaction 27964 27977	muscle spasms
T901	adversereaction 28029 28047	pulmonary embolism
T903	adversereaction 28095 28131	Secondary acute myelogenous leukemia
T905	adversereaction 28174 28193	erythema multiforme
T907	adversereaction 28195 28219	Stevens-Johnson syndrome
T909	adversereaction 28221 28247	toxic epidermal necrolysis
T911	adversereaction 28249 28274	Secondary oral neoplasms:
T913	tradename 28381 28386	DOXIL
T915	tradename 28455 28460	DOXIL
T917	tradename 28553 28558	DOXIL
T919	routeofadministration 28622 28633	intravenous
T921	tradename 29146 29151	DOXIL
T923	dose 29180 29187	1 mg/kg
T925	frequency 29187 29191	/day
T927	dose 29241 29251	0.5 mg/kg/
T929	frequency 29251 29254	day
T931	dose 29323 29331	50 mg/m2
T933	tradename 29494 29499	DOXIL
T935	tradename 29682 29687	DOXIL
T937	tradename 29737 29743	DOXIL.
T939	tradename 29818 29823	DOXIL
T941	tradename 30041 30047	DOXIL.
T943	tradename 30055 30060	DOXIL
T945	tradename 30298 30303	DOXIL
T947	tradename 30391 30396	DOXIL
T949	activeingredient 30480 30496	doxorubicin HCl.
T951	tradename 30569 30574	DOXIL
T953	tradename 30861 30866	DOXIL
T955	tradename 30951 30956	DOXIL
T957	indication 31002 31016	ovarian cancer
T959	indication 31035 31064	AIDS-related Kaposi's sarcoma
T961	tradename 31250 31255	DOXIL
T963	tradename 31524 31529	DOXIL
T965	tradename 31662 31667	DOXIL
T967	activeingredient 31738 31753	doxorubicin HCl
T969	adversereaction 31779 31795	severe mucositis
T971	adversereaction 31797 31807	leukopenia
T973	adversereaction 31813 31829	thrombocytopenia
T975	tradename 31846 31851	DOXIL
T977	activeingredient 31853 31868	doxorubicin HCl
T979	nanoparticle 31869 31877	liposome
T981	activeingredient 31892 31917	doxorubicin hydrochloride
T983	chemoclass 31928 31968	anthracycline topoisomerase II inhibitor
T985	nanoparticle 31994 32011	STEALTH liposomes
T987	routeofadministration 32016 32027	intravenous
T989	activeingredient 32055 32070	doxorubicin HCl
T991	molecularweight 32292 32299	579.99.
T993	tradename 32330 32335	DOXIL
T995	nanoparticle 32367 32376	liposomal
T997	activeingredient 32465 32480	doxorubicin HCl
T999	nanoparticle 32532 32548	STEALTH liposome
T1001	corecomposition 32574 32585	cholesterol
T1003	corecomposition 32605 32648	hydrogenated soy phosphatidylcholine (HSPC)
T1005	surfacecoating 32666 32712	N-(carbonyl-methoxypolyethylene glycol 2000)-1
T1007	surfacecoating 32713 32777	2-distearoyl-sn-glycero3-phosphoethanolamine sodium (MPEG-DSPE)
T1009	inactiveingredient 32813 32829	ammonium sulfate
T1011	inactiveingredient 32851 32860	histidine
T1013	inactiveingredient 32874 32891	hydrochloric acid
T1015	inactiveingredient 32899 32915	sodium hydroxide
T1017	inactiveingredient 32936 32943	sucrose
T1019	nanoparticle 33021 33039	STEALTH liposomes.
T1021	surfacecoating 33041 33050	MPEG-DSPE
T1023	nanoparticle 33111 33128	STEALTH liposome:
T1025	tradename 33196 33201	DOXIL
T1027	activeingredient 33205 33221	doxorubicin HCl.
T1029	activeingredient 33249 33264	doxorubicin HCl
T1031	activeingredient 33622 33633	doxorubicin
T1033	tradename 33661 33666	DOXIL
T1035	activeingredient 33763 33774	Doxorubicin
T1037	tradename 33780 33785	DOXIL
T1039	indication 33803 33832	AIDS-Related Kaposi's Sarcoma
T1041	dose 33857 33874	10 mg/m2 20 mg/m2
T1043	cmax 33934 33945	4.12 0.215
T1045	clearance 33946 33957	0.056 0.01
T1047	cmax 33959 33969	8.34 0.49
T1049	clearance 33970 33982	0.041 0.004
T1051	volumeofdistribution 34016 34046	(L/m2) 2.83 0.145 2.72 0.120
T1053	auc 34051 34079	(g/mL h) 277 32.9 590 58.7
T1055	plasmahalflife 34106 34127	(h) 4.7 1.1 5.2 1.4
T1057	plasmahalflife 34155 34178	(h) 52.3 5.6 55.0 4.8
T1059	tradename 34201 34206	DOXIL
T1061	dose 34259 34274	10 to 20 mg/m2.
T1063	tradename 34287 34292	DOXIL
T1065	dose 34311 34319	20 mg/m2
T1067	activeingredient 34351 34362	doxorubicin
T1069	dose 34375 34383	50 mg/m2
T1071	tradename 34384 34389	DOXIL
T1073	tradename 34453 34458	DOXIL
T1075	dose 34507 34515	20 mg/m2
T1077	nanoparticle 34559 34568	liposomal
T1079	activeingredient 34569 34580	doxorubicin
T1081	activeingredient 34670 34682	doxorubicin)
T1083	nanoparticle 34691 34712	liposome-encapsulated
T1085	activeingredient 34749 34760	doxorubicin
T1087	volumeofdistribution 34815 34832	700 to 1100 L/m2)
T1089	nanoparticle 34883 34892	liposomal
T1091	activeingredient 34893 34904	doxorubicin
T1093	tradename 34919 34924	DOXIL
T1095	activeingredient 34964 34975	Doxorubicin
T1097	nanoparticle 35004 35013	liposomes
T1099	tradename 35058 35063	DOXIL
T1101	activeingredient 35119 35130	doxorubicin
T1103	activeingredient 35205 35216	doxorubicin
T1105	dose 35309 35323	10 or 20 mg/m2
T1107	tradename 35324 35330	DOXIL.
T1109	activeingredient 35375 35386	doxorubicin
T1111	tradename 35392 35397	DOXIL
T1113	clearance 35402 35414	0.041 L/h/m2
T1115	dose 35428 35436	20 mg/m2
T1117	activeingredient 35467 35482	doxorubicin HCl
T1119	activeingredient 35508 35519	doxorubicin
T1121	clearance 35523 35538	24 to 35 L/h/m2
T1123	tradename 35693 35698	DOXIL
T1125	activeingredient 35708 35719	doxorubicin
T1127	tradename 36013 36018	DOXIL
T1129	dose 36128 36136	36 mg/kg
T1131	dose 36156 36164	50 mg/m2
T1133	dose 36281 36291	0.25 mg/kg
T1135	frequency 36291 36295	/day
T1137	dose 36318 36326	50 mg/m2
T1139	dose 36495 36502	1 mg/kg
T1141	frequency 36502 36506	/day
T1143	dose 36528 36536	50 mg/m2
T1145	indication 36586 36600	Ovarian Cancer
T1147	tradename 36602 36607	DOXIL
T1149	indication 36691 36716	metastatic ovarian cancer
T1151	tradename 36978 36983	DOXIL
T1153	dose 36987 36995	50 mg/m2
T1155	frequency 36996 37014	every 3 or 4 weeks
T1157	duration 37019 37030	3-6+ cycles
T1159	indication 37768 37782	Ovarian Cancer
T1161	indication 37799 37813	Ovarian Cancer
T1163	indication 38356 38370	ovarian cancer
T1165	tradename 38449 38454	DOXIL
T1167	dose 38455 38463	50 mg/m2
T1169	frequency 38464 38477	every 4 weeks
T1171	dose 38499 38508	1.5 mg/m2
T1173	frequency 38509 38514	daily
T1175	frequency 38538 38551	every 3 weeks
T1177	tradename 39300 39305	DOXIL
T1179	tradename 40031 40037	DOXIL.
T1181	indication 40092 40121	AIDS-Related Kaposi's Sarcoma
T1183	tradename 40122 40127	DOXIL
T1185	dose 40201 40209	20 mg/m2
T1187	frequency 40210 40223	every 3 weeks
T1189	activeingredient 40663 40679	doxorubicin HCl.
T1191	duration 40710 40720	5.1 months
T1193	duration 40728 40747	1 day to 15 months)
T1195	tradename 40779 40784	DOXIL
T1197	dose 40789 40798	154 mg/m2
T1199	dose 40806 40822	20 to 620 mg/m2)
T1201	indication 42227 42256	AIDS-Related Kaposi's Sarcoma
T1203	tradename 43144 43149	DOXIL
T1205	indication 43517 43533	Multiple Myeloma
T1207	tradename 43550 43555	DOXIL
T1209	co-administereddrug 43576 43586	bortezomib
T1211	co-administereddrug 43720 43730	bortezomib
T1213	tradename 43853 43858	DOXIL
T1215	dose 43860 43869	30 mg/m2)
T1217	routeofadministration 43883 43885	IV
T1219	co-administereddrug 43905 43915	bortezomib
T1221	dose 43917 43926	1.3 mg/m2
T1223	routeofadministration 43927 43929	IV
T1225	frequency 43975 43988	every 3 weeks
T1227	duration 43993 44007	up to 8 cycles
T1229	indication 44288 44304	multiple myeloma
T1231	tradename 44420 44425	DOXIL
T1233	co-administereddrug 44428 44438	bortezomib
T1235	indication 45026 45042	Multiple Myeloma
T1237	tradename 45602 45607	DOXIL
T1239	co-administereddrug 45610 45620	bortezomib
T1241	tradename 45822 45827	DOXIL
T1243	co-administereddrug 45848 45858	Bortezomib
T1245	indication 45893 45909	Multiple Myeloma
T1247	tradename 45920 45925	DOXIL
T1249	co-administereddrug 45928 45938	bortezomib
T1251	tradename 46522 46528	DOXIL+
T1253	co-administereddrug 46528 46539	bortezomib.
T1255	tradename 46841 46846	DOXIL
T1257	nanoparticle 46878 46887	liposomal
T1259	activeingredient 46975 46990	doxorubicin HCl
T1261	activeingredient 47055 47070	doxorubicin HCl
T1263	tradename 47316 47321	DOXIL
T1265	tradename 47379 47384	DOXIL
T1267	adversereaction 47493 47499	Advise
T1269	adversereaction 47574 47587	heart failure
T1271	adversereaction 47626 47642	Infusion-Related
T1273	adversereaction 47644 47650	Advise
T1275	adversereaction 47682 47708	infusion related reactions
T1277	adversereaction 47826 47832	Advise
T1279	adversereaction 47895 47900	fever
T1281	adversereaction 47916 47925	infection
T1283	adversereaction 47927 47945	Hand-Foot Syndrome
T1285	adversereaction 48017 48025	tingling
T1287	adversereaction 48029 48036	burning
T1289	adversereaction 48038 48045	redness
T1291	adversereaction 48047 48054	flaking
T1293	adversereaction 48056 48075	bothersome swelling
T1295	adversereaction 48077 48091	small blisters
T1297	adversereaction 48096 48158	small sores on the palms of their hands or soles of their feet
T1299	adversereaction 48172 48191	Hand-Foot Syndrome)
T1301	adversereaction 48230 48240	Stomatitis
T1303	adversereaction 48317 48324	redness
T1305	adversereaction 48326 48334	swelling
T1307	adversereaction 48339 48357	sores in the mouth
T1309	adversereaction 48371 48382	stomatitis)
T1311	adversereaction 48386 48406	Embryofetal Toxicity
T1313	tradename 48764 48769	DOXIL
T1315	tradename 48867 48872	DOXIL
T1317	adversereaction 48921 48932	Infertility
T1319	tradename 48989 48994	DOXIL
T1321	adversereaction 49028 49039	infertility
T1323	adversereaction 49081 49119	Discoloration of Urine and Body Fluids
T1325	tradename 49151 49156	DOXIL
T1327	company 49383 49399	ALZA Corporation
T1329	company 49416 49436	TTY Biopharm Company
T1331	company 49522 49538	Janssen Products
T1333	company 49540 49542	LP
T1335	company 49563 49579	Janssen Products
T1337	company 49581 49583	LP
T1339	tradename 49641 49646	DOXIL
T1341	company 49676 49693	ALZA Corporation.
